- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05565378
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, Argentina, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
- GSK Investigational Site
-
Florida, Argentina, 1602
- GSK Investigational Site
-
Mar del Plata, Argentina, 7600
- GSK Investigational Site
-
San Juan, Argentina, J5402DIL
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Wilrijk, Belgium, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, Brazil, 14784-400
- GSK Investigational Site
-
Porto Alegre, Brazil, 90610-000
- GSK Investigational Site
-
São Paulo, Brazil, 01246-000
- GSK Investigational Site
-
Vitória, Brazil, 29043-260
- GSK Investigational Site
-
-
-
-
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Tampere, Finland, 33520
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
Vaasa, Finland, 65130
- GSK Investigational Site
-
-
-
-
-
Bordeaux, France, 33076
- GSK Investigational Site
-
Caen, France, 14033
- GSK Investigational Site
-
Marseille, France, 13009
- GSK Investigational Site
-
Quimper, France, 29107
- GSK Investigational Site
-
Strasbourg, France, 67091
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 13125
- GSK Investigational Site
-
Heidelberg, Germany, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Germany, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Germany, 07747
- GSK Investigational Site
-
-
-
-
-
Athens, Greece, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, Greece, 57001
- GSK Investigational Site
-
Thessaloniki, Greece, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, Greece, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, Greece, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Greece, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, Greece, 411 10
- GSK Investigational Site
-
-
-
-
-
Budapest, Hungary, H-1121
- GSK Investigational Site
-
Gyöngyös, Hungary, 3200
- GSK Investigational Site
-
Tatabánya, Hungary, 2800
- GSK Investigational Site
-
-
-
-
-
Avellino, Italy, 83100
- GSK Investigational Site
-
Bergamo, Italy, 24125
- GSK Investigational Site
-
Pisa, Italy, 57124
- GSK Investigational Site
-
Verona, Italy, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, Italy, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Hyōgo, Japan, 673-8558
- GSK Investigational Site
-
Kanagawa, Japan, 241-8515
- GSK Investigational Site
-
Osaka, Japan, 590-0197
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
-
-
-
-
Guadajalara, Mexico, 44280
- GSK Investigational Site
-
San Luis Potosí City, Mexico, 78209
- GSK Investigational Site
-
-
-
-
-
Enschede, Netherlands, 7512 KZ
- GSK Investigational Site
-
Groningen, Netherlands, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, Netherlands, 8934 AD
- GSK Investigational Site
-
Utrecht, Netherlands, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Lublin, Poland, 20-954
- GSK Investigational Site
-
Prabuty, Poland, 82-550
- GSK Investigational Site
-
Siedlce, Poland, 08-110
- GSK Investigational Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- GSK Investigational Site
-
Lisbon, Portugal, 1500-650
- GSK Investigational Site
-
Lisbon, Portugal, 1998-018
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, Portugal, 4434-502
- GSK Investigational Site
-
-
-
-
-
Cape Town, South Africa, 7570
- GSK Investigational Site
-
Parktown, South Africa, 2193
- GSK Investigational Site
-
-
-
-
-
Incheon, South Korea, 21565
- GSK Investigational Site
-
Seoul, South Korea, 03080
- GSK Investigational Site
-
Seoul, South Korea, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, South Korea, 442-723
- GSK Investigational Site
-
-
-
-
-
Badajoz, Spain, 06080
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, Spain, 35016
- GSK Investigational Site
-
Madrid, Spain, 28041
- GSK Investigational Site
-
Madrid, Spain, 28046
- GSK Investigational Site
-
Madrid, Spain, 28027
- GSK Investigational Site
-
Málaga, Spain, 29010
- GSK Investigational Site
-
PamplonaNavarra, Spain, 28027
- GSK Investigational Site
-
Valencia, Spain, 46026
- GSK Investigational Site
-
Valencia, Spain, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10210
- GSK Investigational Site
-
Chiang Mai, Thailand, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, Thailand, 90110
- GSK Investigational Site
-
Khon Kaen, Thailand, 40002
- GSK Investigational Site
-
Pathum Thani, Thailand, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, Turkey (Türkiye), 06800
- GSK Investigational Site
-
Ankara, Turkey (Türkiye), 06680
- GSK Investigational Site
-
Antalya, Turkey (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Turkey (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, Turkey (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, United Arab Emirates
- GSK Investigational Site
-
Abu Dhabi, United Arab Emirates, 51900
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, United Kingdom, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, United Kingdom, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, United Kingdom, HA6 2RN
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, United States, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
Experimental: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
Other Names:
|
|
Experimental: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
Other Names:
Dostarlimab will be administered
Other Names:
|
|
Experimental: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
Other Names:
Dostarlimab will be administered
Other Names:
|
|
Experimental: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
Other Names:
Dostarlimab will be administered
Other Names:
|
|
Experimental: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
Other Names:
Nelistotug will be administered.
Other Names:
Dostarlimab will be administered
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 228 weeks
|
Up to 228 weeks
|
|
Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuation
Time Frame: Up to 228 weeks
|
Up to 228 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 213824
- 2021-005115-32 (EudraCT Number)
- GALAXIES LUNG-201 (Other Identifier: Study Identifier)
- 2023 (U.S. NIH Grant/Contract)
- 2023-505057-40-00 (Registry Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.